Welcome to our dedicated page for Stryker SEC filings (Ticker: SYK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SEC filings for Stryker are dense with surgical device specifications, FDA status updates, and acquisition details—exactly the kind of technical data investors cannot ignore. Digging for when a hip-implant recall was disclosed or how much the Mako robotic arm division contributed can mean scrolling through hundreds of pages. That complexity drives the most common questions we hear: “Where can I find Stryker’s quarterly earnings report 10-Q filing?” or “How do I track Stryker insider trading Form 4 transactions in real time?”
Stock Titan solves these challenges with AI-powered summaries that translate legal language into plain English. Open any Stryker annual report 10-K simplified by our engine and jump straight to segment revenue, R&D spend, or product liability reserves. Our platform refreshes the moment a document hits EDGAR, so you receive Stryker Form 4 insider transactions real-time, Stryker 8-K material events explained, and Stryker proxy statement executive compensation tables—Stryker SEC filings explained simply.
- AI insights highlight FDA approvals, recalls, and product-pipeline shifts hidden in 8-K filings.
- Compare Orthopaedics, MedSurg, and Neurotechnology margins across periods using interactive 10-Q analytics.
- Set alerts for Stryker executive stock transactions Form 4 to gauge management sentiment before earnings.
Whether you need understanding Stryker SEC documents with AI for due-diligence, or a quick glance at Stryker earnings report filing analysis, we provide complete coverage. Every filing type—10-K, 10-Q, 8-K, S-3, DEF 14A—is indexed, searchable, and paired with expert context on how recalls, acquisitions, or regulatory shifts may impact future cash flows. Save hours, surface the insights that matter, and make informed decisions backed by Stryker’s own disclosures.
Stryker Corp (SYK) reported an insider stock transaction by its Vice President and Chief Financial Officer. On 11/20/2025, the officer sold 165 shares of Stryker common stock at a price of $365.88 per share, coded as a sale transaction. After this trade, the officer beneficially owned 6,694 shares of common stock directly and an additional 287 shares indirectly through a 401(k) plan. The filing indicates it was submitted by an attorney-in-fact on behalf of the reporting person.
Stryker Corp has a Form 144 notice indicating a planned sale of 165 shares of common stock through UBS Financial Services on the NYSE, with an aggregate market value of
The shares to be sold were acquired on
Stryker Corporation officer William E. Berry, Jr., the VP and Chief Accounting Officer, reported several transactions in company stock. On 11/14/2025, he exercised an employee stock option to buy 4,925 shares of common stock at an exercise price of $154.14 per share under the 2011 Long-Term Incentive Plan. On the same date, 2,972 shares were disposed of in a transaction coded “F,” indicating shares withheld to cover taxes at $373.42 per share, and 1,953 shares were sold in an open market transaction coded “S” at $365.49 per share. After these transactions, he directly owned 2,833 shares of Stryker common stock and indirectly owned 613 shares through a 401(k) plan.
Stryker Corporation (SYK): Form 144 notice of proposed sale. A security holder filed to sell up to 2,026 shares of SYK common stock. The filing lists an aggregate market value of $740,482, an approximate sale date of 11/14/2025, and execution on the NYSE through UBS Financial Services Inc.
The shares were acquired on 11/14/2025 via an options exercise, with payment by wire on the same date. Shares outstanding were 382,164,865; this is a baseline figure, not the amount being sold.
Stryker Corp (SYK) director Ronda E. Stryker reported open‑market sales of common stock on 11/05–11/06/2025. The trades were executed in multiple tranches at weighted‑average prices between $349.455 and $359.80 per share.
Following these transactions, 2,702,108 shares were beneficially owned indirectly by a Revocable Trust. Additional holdings shown include 13,578,805 shares indirectly by the L. Lee Stryker Trust, 37,600 shares indirectly by the 1988 William D. Johnston Trust, and 1,213 shares held directly.
SYK filed a Form 144 notice for a proposed secondary sale of 520,000 shares of common stock, with an aggregate market value $184,600,000. The filing lists Apex Clearing as broker and the approximate date of sale 11/05/2025 on the NYSE.
The notice also reports 382,307,000 shares outstanding as context. Acquisition history shows 10,000,000 common shares acquired on 05/01/1974 via an estate division from the Estate of L. Lee Stryker. Recent activity includes the Ronda E Stryker Revocable Trust selling 200,000 shares on 08/06/2025 for $75,283,700 in gross proceeds.
This is a resale by an existing holder; cash proceeds flow to the selling holder rather than the company.
Stryker Corporation reported an insider transaction by its VP, Chief Financial Officer on a Form 4. On 11/01/2025, the officer recorded a transaction in Common Stock with Transaction Code F, involving 404 shares at $356.24.
Following the transaction, the officer beneficially owned 6,859 shares directly and 287 shares indirectly through a 401(k). A footnote states this total includes 204 shares acquired under the Employee Stock Purchase Plan as of September 30, 2025.
Stryker (SYK) filed its Q3 2025 10‑Q reporting double‑digit top‑line growth. Net sales rose to $6,057 million from $5,494 million, and diluted EPS was $2.22 versus $2.16. For the nine months, revenue reached $17,945 million with diluted EPS of $6.20.
Growth was broad-based: MedSurg and Neurotechnology sales increased 14.4% to $3,803 million, while Orthopaedics rose 3.9% to $2,254 million. Vascular and Neuro Cranial stood out, reflecting the February acquisition of Inari Medical, which added minimally invasive venous thromboembolism products. Operating income was $1,135 million, and net earnings were $859 million.
Cash flow from operations improved to $2,901 million for the nine months, while investing cash flow of $(4,561) million reflected $4,810 million for the Inari acquisition. The company issued $3,000 million of senior notes and repaid $650 million, ending with total debt of $16,595 million and cash of $3,256 million. Stryker completed the sale of its Spinal Implants business. Shares outstanding were 382,423,648 as of September 30, 2025.
Insider transaction summary: Stryker Corporation director and Group President Viju Menon reported a sale of 500 shares of Stryker common stock on 08/25/2025 at a reported price of $390.61 per share. After the sale, Mr. Menon beneficially owns 12,511 shares directly and 197 shares indirectly through a 401(k) plan. The Form 4 was signed by an attorney-in-fact on 08/27/2025.
FAQ
What is the current stock price of Stryker (SYK)?
What is the market cap of Stryker (SYK)?
